key: cord-0699104-t751ewtb
authors: Nguyen, Cristina; Yale, Katerina; Ghigi, Alessandro; Zheng, Kai; Mesinkovska, Natasha Atanaskova; Wambier, Carlos Gustavo; Cadegiani, Flavio Adsuara; Goren, Andy
title: SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional study
date: 2021-03-30
journal: Ann Thyroid
DOI: 10.21037/aot-21-8
sha: 6b7e93a060de90c768ecc9f262b948e6626b5dc3
doc_id: 699104
cord_uid: t751ewtb

nan

to collect thyroid treatment independent of hyper-or hypothyroid diagnosis; including demographics, hospitalizations within 4 weeks (+/− 2 weeks) of COVID-19 testing, and fatalities. COVID-19 patients were identified as having hyper-or hypothyroidism as a comorbidity when the medical history in the medical record mentioned either "hypothyroidism" (ICD-10 code E01.0, E03.1, E03.2, E03.9, E89.0, E06.3) or "hyperthyroidism" (ICD-10 code E05.30, E05.00, P72.1, E05.21, E05.20). These diagnoses were made from primary care providers, endocrinologists, and/or hospital-based medicine teams. Chi-squared tests were used for statistical analysis.

A total of 176,118 patients had COVID-19 tests between March and August 2020, with a 3.87% positive test rate (Table 1) . A total of 1,504 hyperthyroid patients tested for COVID-19 had a 3.39% (n=51) infection rate, with no significant difference compared to those without hyperthyroidism (P=0.3300). This observation remained true when analyzing hyperthyroid men and women separately (P=0.4922, P=0.1971, respectively). Hospitalization rates were similar for patients with hyperthyroidism compared to those without (P=0.4652), and there were no difference in fatalities after positive COVID-19 test (P=0.6590).

A total of 11,375 hypothyroid patients were tested for COVID-19, with a significantly lower infection rate (2.9%, n=330) compared to those without hypothyroidism (P<0.00001), which held true when separately analyzing hypothyroid men (3.32%, P=0.0101) and women (2.75%, P=0.00002). Furthermore, there was no significant difference in hospitalization rate (P=0.4405). However, when analyzing genders separately, hypothyroid men (2.61%, P<0.00001) had a significantly lower rate of hospitalization, while hypothyroid women (7.9%, P<0.00001) had an increased rate (Table 1 ). There were no differences in fatalities after testing positive for COVID-19 for hypothyroid patients compared to those without (P=0.8263).

In this UC CORDS dataset, both hyper-and hypothyroid patients did not have increased risk of COVID-19 infection, hospitalizations, or fatalities. Our findings suggest epidemiologic evidence of an association between hypothyroidism and reduced SARS-CoV-2 infectivity. Although we hypothesized that T3 is associated with SARS-CoV-2 infectivity through furin expression, our study showed a lower rate of infection for hypothyroid patients. This may be explained by lung tissue T3 activation through type 2 iodothyronine deiodinase (6) likely influencing inflammation, rather than being furin dependent. Also, inhaled liothyronine can inhibit lung fibrosis in rats, and there are currently clinical trials for liothyronine as treatment for acute respiratory distress syndrome, including patients with COVID-19 (7). This study was a retrospective study using data collected from the UC CORDS database of ambulatory and hospitalized COVID-19 patients. A limitation of this study is that our study population consisted solely of patients within a California-based population; therefore, limiting the generalizability of our results. Furthermore, we were unable to collect data for covariates, comorbidities, or whether patients were on thyroid hormone replacement therapy. Other study limitations include use of deidentified, tertiary center data, lack of clinical details, and rapidly changing testing criteria and availability. Future research to understand the mechanisms underlying enhanced COVID-19 susceptibility and disease severity for thyroid dysfunction will be fundamental to developing new therapies for populations at risk through large scale clinical trials.

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The Role of Thyroid Hormone in the Innate and Adaptive Immune Response during Infection

University of California Health Creates Centralized Data Set To Accelerate COVID-19 Research 2020

Scope and limitations of iodothyronine deiodinases in hypothyroidism

Thyroid hormone inhibits lung fibrosis in mice by improving epithelial mitochondrial function

65) four weeks (+/− 2 weeks) of COVID-19 test ‡ death any time after COVID-19 test. * denotes vulues included within the text and significant values

Author manuscript; available in PMC